Research Topics
Genomes and Genes
| Arlene B ChapmanSummaryAffiliation: Emory University School of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertensionVincent J Canzanello
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
Am J Hypertens 21:61-6. 2008..Response to antihypertensive drugs varies widely among individuals...
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazideJulio D Duarte
Center for Pharmacogenomics and Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL 32610, USA
J Transl Med 10:56. 2012..This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure...- Kidney volume and functional outcomes in autosomal dominant polycystic kidney diseaseArlene B Chapman
Emory University School of Medicine, Atlanta, GA 30322, USA
Clin J Am Soc Nephrol 7:479-86. 2012..Autosomal dominant polycystic kidney disease (ADPKD) is characterized by increased total kidney volume (TKV) and renal failure. This study aimed to determine if height-adjusted TKV (htTKV) predicts the onset of renal insufficiency... - Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertensionArlene B Chapman
Renal Division, Department of Medicine, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA
Kidney Int 61:1047-55. 2002.... - Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohortArlene B Chapman
Department of Medicine Renal Division, University of Alabama at Birmingham, Birmingham, Alabama, USA
Kidney Int 64:1035-45. 2003.... - Cystic disease in women: clinical characteristics and medical managementArlene B Chapman
Department of Medicine Renal Division, Emory University School of Medicine, Atlanta, GA, USA
Adv Ren Replace Ther 10:24-30. 2003..Finally, increasing pregnancy number has minimal or no effect on renal outcome in ADPKD women... - The HALT polycystic kidney disease trials: design and implementationArlene B Chapman
Emory University School of Medicine, Atlanta, GA 30322, USA
Clin J Am Soc Nephrol 5:102-9. 2010..Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50% reduction of baseline estimated eGFR, ESRD, or death, respectively... - Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure responseStephen T Turner
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Transl Med 10:47. 2012.... - Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertensionStephen T Turner
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Am J Hypertens 23:1014-22. 2010..Whether these or other characteristics predict blood pressure responses when the drugs are administered as add-on therapy is uncertain... - Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)W CHARLES O'NEILL
Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
Am J Kidney Dis 46:1058-64. 2005..The accuracy and precision of ultrasonography (US) in assessing the severity of autosomal dominant polycystic kidney disease (ADPKD) is unknown... - Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blockerStephen T Turner
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
Hypertension 59:1204-11. 2012.... - Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney diseaseBernard F King
Department of Medicine (Renal Division, University of Alabama, Birmingham, Alabama, USA
Kidney Int 64:2214-21. 2003.... - Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohortAndrew D Rule
Division of Nephrology, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, and University of Alabama, Birmingham, USA
J Am Soc Nephrol 17:854-62. 2006..Misclassification from changes in non-GFR factors (e.g., creatinine production, tubular secretion) conservatively biased associations with eGFR. Misclassification from method imprecision attenuated associations with creatinine clearance... - Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysisDana Rizk
Departments of Medicine and Radiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Clin J Am Soc Nephrol 4:560-6. 2009..This study determined the impact of pain medication use and other clinical, biochemical and genetic characteristics on the physical and mental well being of predialysis ADPKD patients using the Short Form 36 (SF-36) questionnaire... 
Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjectsSamuel Dambreville
Georgia Institute of Technology, Atlanta, Georgia, USA
Magn Reson Med 63:940-50. 2010..8 mL/min (4.21%) for immediate repetition of the breath-held flow scan, 39.13 mL/min (6.90%) for repeated plane scouting, and 40.76 mL/min (7.20%) for weekly fluctuations in renal blood flow...- Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazideAmber L Beitelshees
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
J Clin Hypertens (Greenwich) 12:14-21. 2010..58) than with OBP response (r=0.47; P=.04). In the context of a randomized clinical trial, the authors have identified significant differences in HBP, OBP, and ABP methods of measuring BP response to atenolol and HCTZ monotherapy... - Renal CD14 expression correlates with the progression of cystic kidney diseaseJuling Zhou
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Kidney Int 78:550-60. 2010..But the association was significant when the analysis was confined to males. Clearly more studies need to be done to evaluate the utility of CD14 as a marker for outcomes in ADPKD... - Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studiesArlene B Chapman
Emory University School of Medicine, 1364 Clifton Road, Room GG23, Atlanta, GA 30322, USA
Clin J Am Soc Nephrol 3:1197-204. 2008..Findings from CRISP and the rationale for interventions in ADPKD are described, and the design of the HALT-PKD clinical trial is outlined... - Hypertension in autosomal dominant polycystic kidney diseaseArlene B Chapman
Emory University School of Medicine, Atlanta, GA, USA
Adv Chronic Kidney Dis 17:153-63. 2010..Currently, large multicenter studies are being performed to determine the beneficial effects of RAAS inhibition both early and late in ADPKD... - Cystic and inherited kidney diseasesDana Rizk
Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
Am J Kidney Dis 42:1305-17. 2003 - Autosomal dominant polycystic kidney disease: time for a change?Arlene B Chapman
Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA
J Am Soc Nephrol 18:1399-407. 2007.... - Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKDArlene B Chapman
Emory University School of Medicine, Atlanta, Georgia 30322, USA
Kidney Int 75:139-41. 2009..These powerful and exciting tools make it possible to consider both short and long term randomized clinical trials in ADPKD at various stages of disease. Highlights of the work by Kistler and colleagues are now provided... - The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney diseaseRobert W Schrier
Department of Medicine, University of Colorado School of Medicine, Denver, Colorado 80262, USA
Kidney Int 64:1792-9. 2003..The present study was undertaken to examine the role of parental hypertension in the occurrence of hypertension in 475 ADPKD offspring... - Imaging approaches to patients with polycystic kidney diseaseArlene B Chapman
Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, GA, USA
Semin Nephrol 31:237-44. 2011..Renal blood flow and a novel approach to interpreting noncystic renal parenchyma by computed tomography images are other innovative imaging approaches described... - Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocolsDiego R Martin
Department of Radiology, Emory University, Atlanta, Georgia, USA
J Magn Reson Imaging 31:440-6. 2010.... - Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney diseaseMark M Belz
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
Kidney Int 63:1824-30. 2003..CONCLUSION: Individuals with ADPKD and ICA appear to be at moderate risk for new ICAs and increase in size of existing ICAs; mortality and risk of recurrent rupture, however, appear to be low... - Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndromeMark B Consugar
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Kidney Int 74:1468-79. 2008..Our assay improves detection levels and the reliability of molecular testing of patients with ADPKD... - Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazideJavier Daniel Finkielman
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
Am J Hypertens 18:398-402. 2005..Variation among subjects in the magnitude and direction of responses renders OBP an unreliable predictor of ABPM responses... - Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjectsAnke Hilse Maitland-van der Zee
Human Genetics Center, University of Texas Health Science Centre, Houston, TX 77030, USA
Am J Hypertens 18:1077-83. 2005..The aim of this study was to characterize interindividual variation in glucose and lipid responses to hydrochlorothiazide and to identify demographic, environmental, and genetic predictors associated with this variation... - WNK1 kinase polymorphism and blood pressure response to a thiazide diureticStephen T Turner
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, USA
Hypertension 46:758-65. 2005..Polymorphisms in genes regulating renal sodium transport, in particular WNK1, predict interindividual differences in antihypertensive responses to hydrochlorothiazide... - A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazideAnke Hilse Maitland-van der Zee
Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
Pharmacogenet Genomics 15:287-93. 2005..To assess the influence of variations in multiple candidate genes on inter-individual variation in diastolic blood pressure (DBP) response to hydrochlorothiazide... - Volume progression in polycystic kidney diseaseJared J Grantham
Kidney Institute and the Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA
N Engl J Med 354:2122-30. 2006..Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive enlargement of cyst-filled kidneys... - Reproducibility of blood pressure response to hydrochlorothiazideJavier D Finkielman
Division of Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
J Clin Hypertens (Greenwich) 4:408-12. 2002..These results show that the average systolic and diastolic blood pressure responses to hydrochlorothiazide for a group of subjects are reproducible; however, the responses for individual subjects are unpredictable... - Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney diseaseVicente E Torres
Mayo Clinic College of Medicine, Rochester, MN 55901, USA
Clin J Am Soc Nephrol 2:112-20. 2007..TKV and RBF were independent predictors of GFR decline (functional disease progression). In ADPKD, RBF reduction (1) parallels TKV increase, (2) precedes GFR decline, and (3) predicts structural and functional disease progression... - Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazideStephen T Turner
Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Am J Hypertens 16:834-9. 2003.... - Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratioGary L Schwartz
Division of Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Clin Chem 48:1919-23. 2002..We determined the sensitivity, specificity, and predictive value of the ratio to identify combinations of renin and aldosterone compatible with primary aldosteronism... - Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohortKyongtae T Bae
Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
Clin J Am Soc Nephrol 1:64-9. 2006..Hepatic cysts are more prevalent and larger in total cyst volume in women than in men. Hepatic cyst prevalence and aggregate total hepatic cyst volume increased with age... - Comprehensive molecular diagnostics in autosomal dominant polycystic kidney diseaseSandro Rossetti
Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
J Am Soc Nephrol 18:2143-60. 2007..Although nondefinite mutation data must be treated with care in the clinical setting, this study shows the potential for molecular diagnostics in ADPKD that is likely to become increasingly important as therapies become available... - Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diureticStephen T Turner
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
Hypertension 52:359-65. 2008..These results support the use of genome-wide association analyses to identify novel genes influencing antihypertensive drug responses... - Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney diseasePeter C Harris
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Am Soc Nephrol 17:3013-9. 2006..These insights will inform the development of targeted therapies in autosomal dominant PKD... - Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomesJared J Grantham
Kansas University Medical Center, Kansas City, Kansas, USA
Clin J Am Soc Nephrol 1:148-57. 2006.... - Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazideGary L Schwartz
Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Kidney Int 62:1718-23. 2002..The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene is associated with variation in serum ACE activity and may influence BP in a gender-specific manner...
Research Grants
- Symposium for Molecular and Therapeutic Insights in PKDArlene Chapman; Fiscal Year: 2002..Day 5 will be devoted to autosomal recessive kidney diseases and the last half day will be devoted to potential therapeutic strategies in cystic disorders of the kidney. ..
- "The Early Collaborative Clinical Studies in PKD: The C*Arlene Chapman; Fiscal Year: 2007....
- Polycystic Kidney Disease Clinical Trials NetworkArlene Chapman; Fiscal Year: 2006..Ultimately these studies should demonstrate slowing or halting progression of ADPKD. ..